Welcome to our dedicated page for Owens & Minor SEC filings (Ticker: OMI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SEC filings associated with Owens & Minor, Inc. (historically NYSE: OMI) provide detailed documentation of the company’s transformation into Accendra Health, Inc. and its strategic focus on home-based care. Forms 8-K describe key events such as the entry into and completion of the Equity Purchase Agreement for the sale of the Products & Healthcare Services (P&HS) segment, the structure of the consideration received, and the company’s retained equity interest in the divested business. These filings also outline related credit facility amendments, receivables sale programs, and the release of certain subsidiaries from guarantees under term loan and note indentures.
Investors can use this filings page to access current and historical 8-K reports that explain material events, including transaction terms, transition services arrangements, and changes to executive compensation and retirement plans. The filings also document the name change from Owens & Minor, Inc. to Accendra Health, Inc. through Articles of Amendment and amended bylaws, and they state that the company expects its common stock to begin trading on the New York Stock Exchange under the ticker symbol ACH. These disclosures clarify how the legacy OMI symbol relates to the continuing entity.
Quarterly and annual reports (Forms 10-Q and 10-K, when accessed through EDGAR) provide more comprehensive information about the company’s segments, including the classification of the P&HS segment as discontinued operations and the description of continuing operations as primarily representing the Patient Direct segment and certain functional operations. They also include discussions of risk factors, capital structure, and accounting treatment of receivables sale arrangements.
On Stock Titan’s SEC filings page, users can review these documents as they are made available from EDGAR and take advantage of AI-powered tools that summarize complex disclosures. These tools can help highlight the implications of major transactions, the impact of the P&HS divestiture on the company’s financial statements, and the significance of the corporate name and ticker change for holders of the legacy OMI shares.
Owens & Minor (OMI): Coliseum Capital filed a Schedule 13D, replacing its prior 13G and signaling a more active posture. The reporting group—Coliseum Capital Management, Coliseum Capital, Coliseum Capital Partners, and principals Adam Gray and Christopher Shackelton—disclosed beneficial ownership of 13,100,807 shares, representing 16.9% of the common stock.
Coliseum states the stake was acquired for investment purposes and outlines potential actions under Item 4, including discussions with management and other stakeholders and evaluating proposals related to operations, governance, capitalization, business combinations, asset sales, or financing transactions. As context, Coliseum Capital Partners is the record owner of 10,657,337 shares and a separate account managed by Coliseum holds 2,443,470 shares. Shares outstanding were 77,346,594 as of October 24, 2025. The group reported no transactions in the 60 days preceding this filing.
Owens & Minor (OMI) filed its Q3 2025 10‑Q, highlighting modest growth in continuing operations but large losses tied to the pending divestiture of its Products & Healthcare Services (P&HS) segment. Net revenue from continuing operations was $697,264 for the quarter, up slightly from $686,846. Continuing operations posted an operating income of $26,470, but interest and other items drove a loss before taxes of $(3,635).
The company recorded a Q3 net loss of $(150,276), largely due to discontinued operations. Year‑to‑date, the net loss reached $(1,044,316), reflecting a $771,640 loss on classification of P&HS as held‑for‑sale and a $106,389 goodwill impairment. OMI also paid an $80,000 transaction breakage fee for terminating a prior acquisition.
On October 7, 2025, OMI signed an agreement to sell P&HS for $375 million in cash, retain a 5% equity interest, and included termination fees of $9.4 million or $19 million; closing is expected in the first quarter of 2026, subject to customary approvals. As of September 30, 2025, total debt was $2,115,261 with $270,700 drawn on the revolver and $280,000 due within twelve months. Equity swung to a deficit of $(429,507). Concentration risk rose as the largest commercial payor plans to terminate contracts representing $242,000 (12%) of nine‑month net revenue, including $173,000 of capitation revenue.
Owens & Minor (OMI) furnished materials related to its results of operations. The company issued a press release covering financial results for the third quarter and nine months ended September 30, 2025, and made an earnings presentation available on its investor relations website.
Both documents were furnished, not filed, under Items 2.02 and 7.01, respectively, and are included as Exhibits 99.1 and 99.2. As furnished materials under General Instruction B.2, they are not subject to Section 18 liability or incorporated by reference unless specifically referenced.
The Vanguard Group filed an amended Schedule 13G reporting beneficial ownership of 5,962,847 shares of Owens & Minor (OMI) common stock, representing 7.71% of the class as of 09/30/2025.
Vanguard reports 0 shares with sole voting power and 739,487 with shared voting power. It has 5,153,718 shares with sole dispositive power and 809,129 with shared dispositive power. The filer is classified as an investment adviser (IA) and certifies the holdings were acquired and are held in the ordinary course, not to change or influence control.
Dimensional Fund Advisors LP filed an amended Schedule 13G reporting beneficial ownership of 3,507,559 shares of Owens & Minor Inc common stock, representing
Owens & Minor, Inc. agreed to sell its Products & Healthcare Services business (O&M PHS LLC) to Dominion Healthcare Acquisition Corporation for
The Equity Purchase Agreement and a company press release are dated
Owens & Minor insider transaction: Jonathan A. Leon, EVP & CFO of Owens & Minor (OMI), reported a transaction dated 09/23/2025 in which 4,265 shares of the company's common stock were disposed at a reported price of $5.40 per share. The filing states these shares were surrendered to the issuer to satisfy tax withholding obligations arising from the vesting of restricted stock. After the disposal, Mr. Leon is reported to beneficially own 218,522 shares directly. The Form 4 was signed by a power of attorney on 09/24/2025.
Owens & Minor, Inc. reports that its Executive Vice President and Chief Information Officer, Snehashish Sarkar, has resigned from the company. He notified Owens & Minor on September 15, 2025 that he will leave his role effective September 26, 2025 to pursue another opportunity.
Sarkar has served as Chief Information Officer since October 2022. The company notes that during his tenure he built a strong global information technology team that is described as well-prepared to continue supporting Owens & Minor’s strategic priorities after his departure.
Coliseum Capital affiliates reported multiple open-market purchases of Owens & Minor, Inc. (OMI) common stock between 08/12/2025 and 08/14/2025. The filings show purchases of 720,000, 325,000 and 492,852 shares at weighted-average prices of $5.15, $5.46 and $5.31, respectively. After these transactions the reporting persons beneficially owned 13,100,807 shares in the aggregate, held indirectly through Coliseum Capital Partners, L.P. and a separate advisory account; footnotes state CCP directly owned 10,657,337 shares and the Separate Account 2,443,470 shares. No derivative securities were reported.
Owens & Minor reported consolidated results showing continuing operations revenue rose to $681.9 million for the quarter and $1.356 billion for the six months, up from $660.4 million and $1.298 billion a year earlier. Continuing operations produced an operating loss of $39.7 million for the quarter and a pre-tax loss of $84.9 million, after recording an $80 million transaction breakage fee and acquisition-related charges.
The company classified its Products & Healthcare Services (P&HS) segment as discontinued operations and held-for-sale, recognizing a $106.4 million goodwill impairment and a $649.1 million loss on classification, contributing to a quarterly net loss of $869.1 million and basic loss per share of $11.30. Total assets were $4.15 billion with total liabilities of $4.44 billion, resulting in a deficit equity of $281.0 million at June 30, 2025. The divestiture process is described as in the final stages.